Natco Pharma Buys Deeper Into Adcock Ingram, Hits 49% Stake

It is the second phase of Natco's move into Adcock Ingram. The Hyderabad-based drugmaker first bought a 35.75% stake during Adcock Ingram's delisting process in 2025, completing that transaction in November 2025.

Adcock Ingram was founded in 1891 and ranks second in South Africa's combined private and public pharmaceutical market. It holds a 10% share of the private market, leads the over-the-counter segment and is the country's biggest supplier of hospital and critical-care products. Its brand stable includes Panado, Allergex and Myprodol.

Natco shares traded at ₹967.70 on the NSE on Tuesday afternoon, down 1.25% from the previous close of ₹979.95. The company has a market capitalisation of roughly ₹17,332 crore and sits on the Nifty Smallcap 100 index.